Casi Pharmaceuticals Inc's Comment on Supply Chain
The company depends on third-party suppliers, including Wuxi, for raw materials, components, and services. Non-performance by these suppliers could delay clinical development, regulatory submissions, or manufacturing operations. While alternative suppliers have been identified, some lack established contractual agreements, which may cause delays if a transition is necessary. Manufacturing challenges, such as deviations from current Good Manufacturing Practices (cGMP), could result in product defects, shipment delays, recalls, or regulatory actions. The Wuxi facility is newly operational with limited regulatory inspection history, leading to increased regulatory scrutiny. Manufacturing pharmaceutical products involves complex, costly processes, including scaling production and maintaining regulatory approvals from authorities such as the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). Compliance with cGMP is essential; failure to maintain it could delay marketing approvals or disrupt product availability.
Casi Pharmaceuticals Inc's Comment on Supply Chain
The company depends on third-party suppliers, including Wuxi, for raw materials, components, and services. Non-performance by these suppliers could delay clinical development, regulatory submissions, or manufacturing operations. While alternative suppliers have been identified, some lack established contractual agreements, which may cause delays if a transition is necessary. Manufacturing challenges, such as deviations from current Good Manufacturing Practices (cGMP), could result in product defects, shipment delays, recalls, or regulatory actions. The Wuxi facility is newly operational with limited regulatory inspection history, leading to increased regulatory scrutiny. Manufacturing pharmaceutical products involves complex, costly processes, including scaling production and maintaining regulatory approvals from authorities such as the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). Compliance with cGMP is essential; failure to maintain it could delay marketing approvals or disrupt product availability.
Sources:
Casi Pharmaceuticals inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Casi Pharmaceuticals inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
